Jyong Biotech Ltd. Chairwoman Invited to Speak at 2025 Global Business Forum

Strategic Insights -

Jyong Biotech Ltd. Chairwoman and CEO Fu Feng Kuo has been invited to speak at The 2025 Global Business Forum, a high-level international business matchmaking platform discussing Taiwan's biotech and medical industries' alignment with global trends. The event, organized by the Taiwanese Chambers of Commerce of North America (TCCNA) in collaboration with U.S. venture capital and biotechnology industry representatives, aims to bring together influential U.S. biotech decision-makers and Taiwan's leading new drug development enterprises. Discussions will focus on three core themes: innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment.

Key Takeaways:

  • Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs, mainly specializing in the treatment of urinary system diseases.
  • The Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates.
  • The Company has built integrated capabilities encompassing all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
  • Jyong Biotech Ltd. is headquartered in Taiwan and has an initial focus on the markets of the U.S., the EU, and Asia.
  • The Chairwoman and CEO, Fu Feng Kuo, will discuss how Taiwan can align its biotech and medical industries with global trends at The 2025 Global Business Forum.
  • The event aims to bring together influential U.S. biotech decision-makers and Taiwan's leading new drug development enterprises for direct dialogue.

Statistics:

  • 2002: The year Jyong Biotech Ltd. was founded.
  • 2002-Present: The date range during which the Company has been developing and commercializing innovative and differentiated new drugs.
  • 2025: The year The 2025 Global Business Forum will take place, where Jyong Biotech Ltd. Chairwoman and CEO Fu Feng Kuo will be speaking.
  • U.S., EU, and Asia: The initial markets Jyong Biotech Ltd. has a focus on.
  • BOTRESO: The primary botanical drug candidate developed by Jyong Biotech Ltd.

Sources:

  • (GLOBE NEWSWIRE, Jyong Biotech Ltd. press release)
  • (Jyong Biotech Ltd. website)
  • (WFS Investor Relations Inc. contact information)